Cereno Scientific AB (CRNO-B) Fair Value & Analysis
Healthcare · SE · Market cap 1.4B SEK
Fair value as of: Jul 16, 2026
From 1 valuation models · updated 5 days ago
Share price −26.6% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 4.40 – kr 10.20 · fair‑value band kr 0.3485 – kr 0.6885 · the kr 4.48 price screens above the kr 0.4590 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Cereno Scientific AB (CRNO-B) currently trades at kr 4.48, while our model-based Fair Value estimate is kr 0.4590, implying the stock looks roughly 89.8% overvalued today. We read business quality at 20/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 66.8M SEK. Revenue grew 137.3% year over year. It earns a return on equity of -61.3%. Net debt stands at 50.4M SEK. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 0.3485 (bear case) to kr 0.6885 (bull case); at kr 4.48, the current price sits above that range. The share trades about 61% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside, at -90%, CRNO-B screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue remodeling, inflammatory processes, pulmonary arterial pressure, thrombotic mechanisms. Its drugs portfolio includes CS014, an epigenetic modulator that is in phase I clinical trial for the treatment of cardiovascular, pulmonary diseases, pulmonary hypertension, and idiopathic pulmonary fibrosis; and preclinical drug candidates comprises CS585, a selective prostacyclin (IP) receptor agonist for the treatment of rare thrombotic diseases. The company has a collaboration agreement with the University of Michigan for …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cereno Scientific AB reported revenue of kr 0 in FY2025 versus kr 0 in FY2021. Reported net income was −kr 118M in FY2025.
Is CRNO-B fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Lupin Limited LUPIN | ₹2,268 | ₹2,697 | +19% |
| Mankind Pharma Limited MANKIND | ₹2,336 | ₹1,068 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cereno Scientific AB (CRNO-B) undervalued?
What is the fair value of CRNO-B?
What is the quality score of CRNO-B?
What is the revenue of Cereno Scientific AB (CRNO-B)?
What is the net profit margin of CRNO-B?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Cereno Scientific AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.